Lexeo Therapeutics (NASDAQ:LXEO) Insider Narinder Pal Bhalla Sells 22,306 Shares

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) insider Narinder Pal Bhalla sold 22,306 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $4.42, for a total transaction of $98,592.52. Following the transaction, the insider directly owned 82,194 shares in the company, valued at approximately $363,297.48. The trade was a 21.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Lexeo Therapeutics Trading Down 4.5%

Lexeo Therapeutics stock traded down $0.21 during midday trading on Wednesday, hitting $4.45. 852,557 shares of the stock were exchanged, compared to its average volume of 948,339. The stock’s 50-day simple moving average is $5.16 and its 200 day simple moving average is $6.67. Lexeo Therapeutics, Inc. has a fifty-two week low of $3.60 and a fifty-two week high of $10.99. The stock has a market capitalization of $349.41 million, a price-to-earnings ratio of -3.07 and a beta of 1.38.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.04. Equities analysts anticipate that Lexeo Therapeutics, Inc. will post -1.21 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. JPMorgan Chase & Co. cut their target price on Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating for the company in a research note on Thursday, June 25th. Chardan Capital reaffirmed a “buy” rating and issued a $17.00 price target on shares of Lexeo Therapeutics in a research note on Monday, May 11th. Wall Street Zen upgraded Lexeo Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Weiss Ratings lowered shares of Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 25th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $18.75.

Institutional Trading of Lexeo Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Allworth Financial LP lifted its stake in Lexeo Therapeutics by 1,002.9% during the fourth quarter. Allworth Financial LP now owns 3,386 shares of the company’s stock worth $34,000 after purchasing an additional 3,079 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Lexeo Therapeutics by 69.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock valued at $35,000 after buying an additional 1,459 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Lexeo Therapeutics in the fourth quarter valued at $37,000. California State Teachers Retirement System raised its holdings in shares of Lexeo Therapeutics by 123.7% in the 4th quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock valued at $39,000 after buying an additional 2,148 shares during the period. Finally, Cerity Partners LLC purchased a new stake in shares of Lexeo Therapeutics in the 2nd quarter valued at $50,000. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.